leisure time -WSS

leisure time

author：Wikipedia 2025-10-01 00:57:51 - browse：69629

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： As biotech industry slumps, bioscience job market is upside down

entertainment

WSS

CDC director unscathed in first congressional testimony

Judge rejects Trump's request to move Stormy Daniels hush

Affordable Connectivity Program vital to health care, experts say

Affordable Connectivity Program vital to health care, experts say

What don’t we know about an Alzheimer’s drug side effect?

Stanford president's case begs question: Who takes blame?

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

Driven by the pandemic, applicants flood public health schools

Tori Bowie and the unacceptable rates of Black maternal death

Disappointing trial forces Pfizer to pivot on obesity medicine plans

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Organ aging and disease risk measured by new blood test

Tori Bowie and the unacceptable rates of Black maternal death

I learned firsthand about improving diversity in clinical trials

Medical records are filled with copy

EF3 tornado rips through North Carolina amid extreme weather nationwide

knowledge

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

As biotech industry slumps, bioscience job market is upside down

Indian pharmaceutical industry in denial over drug

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Stanford president faces new allegations over 1999 paper

Divers poised to search for children washed away in Pennsylvania flash flood

hotspot

entertainment

hotspot

hotspot